Compare Stocks: ARWR, ALNY, ROIV, and GMAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$224.03 -1.4%	$239.80	$197.81 ▼ $485.36	$29.98B	0.28	1.31 million shs	1.06 million shs
ARWR Arrowhead Pharmaceuticals	$58.02 -0.6%	$72.62	$36.88 ▼ $95.49	$8.17B	1.29	1.92 million shs	871,718 shs
GMAB Genmab A/S	$43.79 +9.5%	$35.25	$23.62 ▼ $44.34	$27.33B	0.81	4.48 million shs	13.00 million shs
ROIV Roivant Sciences	$36.49 -2.6%	$36.62	$17.89 ▼ $42.50	$26.36B	1.1	6.40 million shs	8.23 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-3.36%	-10.24%	-17.57%	-51.81%
ARWR Arrowhead Pharmaceuticals	0.00%	+3.79%	-12.18%	-32.22%	+54.19%
GMAB Genmab A/S	0.00%	+18.35%	+25.72%	+51.68%	+46.36%
ROIV Roivant Sciences	0.00%	+8.83%	+1.00%	+4.23%	+103.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$224.03 -1.4%	$239.80	$197.81 ▼ $485.36	$29.98B	0.28	1.31 million shs	1.06 million shs
ARWR Arrowhead Pharmaceuticals	$58.02 -0.6%	$72.62	$36.88 ▼ $95.49	$8.17B	1.29	1.92 million shs	871,718 shs
GMAB Genmab A/S	$43.79 +9.5%	$35.25	$23.62 ▼ $44.34	$27.33B	0.81	4.48 million shs	13.00 million shs
ROIV Roivant Sciences	$36.49 -2.6%	$36.62	$17.89 ▼ $42.50	$26.36B	1.1	6.40 million shs	8.23 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-3.36%	-10.24%	-17.57%	-51.81%
ARWR Arrowhead Pharmaceuticals	0.00%	+3.79%	-12.18%	-32.22%	+54.19%
GMAB Genmab A/S	0.00%	+18.35%	+25.72%	+51.68%	+46.36%
ROIV Roivant Sciences	0.00%	+8.83%	+1.00%	+4.23%	+103.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$364.95	62.90% Upside
ARWR Arrowhead Pharmaceuticals	2.73	Moderate Buy	$99.07	70.75% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$43.39	-0.92% Downside
ROIV Roivant Sciences	2.79	Moderate Buy	$45.64	25.07% Upside

Current Analyst Ratings Breakdown

Latest ARWR, ALNY, ROIV, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/20/2026	GMAB Genmab A/S	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$42.00
10/15/2026	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$550.00 ➝ $354.00
10/15/2026	ARWR Arrowhead Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$63.00 ➝ $109.00
10/15/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$115.00
10/15/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$120.00
10/14/2026	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/14/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$340.00 ➝ $320.00
10/14/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$256.00 ➝ $253.00
10/14/2026	ARWR Arrowhead Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/12/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.07	$2.80 per share	80.12	$5.97 per share	37.53
ARWR Arrowhead Pharmaceuticals	$669.50M	12.21	$0.12 per share	485.93	$3.64 per share	15.94
GMAB Genmab A/S	$3.72B	7.35	$1.61 per share	27.21	$9.10 per share	4.81
ROIV Roivant Sciences	$7.53M	3,499.41	N/A	N/A	$7.35 per share	4.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	41.64	24.25	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	11/24/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	34.48	27.54	2.01	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest ARWR, ALNY, ROIV, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.3671	N/A	N/A	N/A	$3.74 million	N/A
11/5/2026	Q3 2026	GMAB Genmab A/S	$0.37	N/A	N/A	N/A	$1.20 billion	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.66	N/A	N/A	N/A	$1.43 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
GMAB Genmab A/S	0.81	2.46	2.44
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ARWR Arrowhead Pharmaceuticals	62.61%
GMAB Genmab A/S	7.07%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
ARWR Arrowhead Pharmaceuticals	3.60%
GMAB Genmab A/S	1.54%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
ARWR Arrowhead Pharmaceuticals	711	140.86 million	135.79 million	Optionable
GMAB Genmab A/S	3,029	624.06 million	614.45 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

ARWR, ALNY, ROIV, and GMAB Headlines

Recent News About These Companies

Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares

October 24 at 4:40 AM | americanbankingnews.com

Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials

October 23 at 2:46 PM | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Roivant Sciences (ROIV) and 4D Molecular Therapeutics (FDMT)

October 23 at 9:45 AM | theglobeandmail.com

Roivant Sciences (NASDAQ:ROIV) CEO Sells $7,022,000.00 in Stock

October 23 at 4:52 AM | insidertrades.com

Roivant Sciences Ltd. $ROIV Shares Newly Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

October 23 at 4:47 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock

October 22 at 7:07 PM | marketbeat.com

Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease

October 22 at 7:15 AM | biospace.comB

Roivant Sciences Ltd. announces positive results in CLARITY-1 and CLARITY-2 phase 3 trials for brepocitinib

October 22 at 1:28 AM | msn.com

Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

October 21, 2026 | cnbc.com

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

October 21, 2026 | seekingalpha.com

Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results

October 21, 2026 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Gap Up - Here's What Happened

October 21, 2026 | marketbeat.com

Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares Rise

October 21, 2026 | rttnews.com

Roivant Sciences stock surges on positive uveitis trial data

October 21, 2026 | finance.yahoo.com

Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis

October 21, 2026 | finance.yahoo.com

Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win

October 21, 2026 | seekingalpha.com

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

October 21, 2026 | globenewswire.com

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

October 21, 2026 | globenewswire.com

Roivant Sciences (NASDAQ:ROIV) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Review

October 19, 2026 | americanbankingnews.com

Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run

October 18, 2026 | finance.yahoo.com

Roivant Sciences (ROIV) share price

October 16, 2026 | economictimes.indiatimes.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, ALNY, ROIV, and GMAB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$224.03 -3.25 (-1.43%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$226.08 +2.05 (+0.91%)

As of 10/23/2026 07:56 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$58.02 -0.34 (-0.58%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$58.06 +0.04 (+0.08%)

As of 10/23/2026 07:30 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Genmab A/S NASDAQ:GMAB

$43.79 +3.79 (+9.48%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$43.80 +0.01 (+0.02%)

As of 10/23/2026 07:57 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Roivant Sciences NASDAQ:ROIV

$36.49 -0.96 (-2.56%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$36.62 +0.13 (+0.36%)

As of 10/23/2026 08:00 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARWR, ALNY, ROIV, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARWR, ALNY, ROIV, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARWR, ALNY, ROIV, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, ALNY, ROIV, and GMAB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Arrowhead Pharmaceuticals NASDAQ:ARWR

Genmab A/S NASDAQ:GMAB

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARWR, ALNY, ROIV, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARWR, ALNY, ROIV, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARWR, ALNY, ROIV, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, ALNY, ROIV, and GMAB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Arrowhead Pharmaceuticals NASDAQ:ARWR

Genmab A/S NASDAQ:GMAB

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools